Loading data for TEM — first visit, this takes a few seconds.

Preisalarm

Tempus AI Inc. (TEM)

NasdaqGS: TEM · Echtzeitkurs · USD

49.36

-2.28 (-4.42%)

Zum Schluss: Aug 17, 2026, 8:00 PM

50.87

-1.49%

Vorbörslich: 4:46 AM

-4.42% (1D)

Keine Daten verfügbar

Geld	46.47
Marktkapitalisierung	9.32 Mrd
Umsatz (TTM)	1.43 Mrd
Nettogewinn (TTM)	-254.42 Mio
Beta	3.58
EPS (ttm)	-1.43
KGV (TTM)	n/a
Forward-KGV	-3397.37
KBV (TTM)	20.90
KUV (TTM)	6.51
Earnings Date	Nov 3, 2026

Brief	53.85
Volumen	3,491,113
Ø Vol. (20D)	5,880,758
Eröffnung	50.21
Vortagesschluss	51.64
Tagesspanne	49.35 - 51.10
52-Wk Range	40.77 - 104.32
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über TEM

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for he...

[Mehr lesen]

Branche Health Information Services

Sektor Healthcare

IPO Datum Jun 14, 2024

Mitarbeiter 3,800

Börse NasdaqGS

Tickersymbol TEM

Website https://www.tempus.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Tempus AI 1.27 Mrd, ein Anstieg von 83.41% im Vergleich zum Vorjahr (693.4 Mio). Der Gewinn lag bei -245.03 Mio, ein Rückgang von -65.28 %.

Finanzberichte

Gewinnüberraschung

Tempus AI hat die Quartalszahlen am Jul 30, 2026 veröffentlicht:

Umsatz von $382.49 Mio verfehlt die Erwartungen um $0, mit 21.56% Wachstum im Jahresvergleich.

EPS von -0.04 übertrifft die Erwartungen um 0.11, mit 81.82% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Tempus AI Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 3, 2026, während der Handelszeiten.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 5 Tagen · Zacks

Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

vor 6 Tagen · Zacks

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

vor 1 Woche · 24/7 Wall St.

The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed...

vor 1 Woche · Zacks

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

vor 2 Wochen · Simply Wall St.

How Investors May Respond To Tempus AI (TEM) Q2 Profit Return, Outlook Hike, Personalis Deal

In the past week, Tempus AI, Inc. reported second-quarter 2026 results showing revenue of US$382.49 million and a swing from a net loss of US$42.84 million a year ago to net income of US$5.64 million,...

Seite 1 von 2